Sensibilizzazione cutanea: possibilit in vitro. Emanuela Corsini - - PDF document

sensibilizzazione cutanea possibilit in vitro
SMART_READER_LITE
LIVE PREVIEW

Sensibilizzazione cutanea: possibilit in vitro. Emanuela Corsini - - PDF document

Sensibilizzazione cutanea: possibilit in vitro. Emanuela Corsini Laboratory of Toxicology, Department of Pharmacological Sciences, Faculty of Pharmacy, Universit degli Studi di Milano, Milan, Italy PRESENTATION LAYOUT Introduction to


slide-1
SLIDE 1

Sensibilizzazione cutanea: possibilità in vitro.

Emanuela Corsini

Laboratory of Toxicology, Department of Pharmacological Sciences, Faculty of Pharmacy, Università degli Studi di Milano, Milan, Italy

PRESENTATION LAYOUT

  • Introduction to chemical allergy
  • In vivo models
  • In vitro models
slide-2
SLIDE 2

CHEMICAL ALLERGY

  • The two most frequent manifestation of chemical-induced allergy are contact

hypersensitivity and respiratory sensitization, both of which can have serious impact on quality of life and represent a common occupational health problem.

  • Chemical agents cause approximately 40% of cases of occupational asthma.
  • Over the past few decades industrialized countries have faced a significant

increase, although the rate of increase has recently slowed, of allergic diseases like atopic rhinitis, bronchial asthma, urticaria and contact dermatitis.

  • Hypersensitivity reactions are often considered a major health problem in

relation to environmental chemical exposure.

Potential Contact Sensitizers Potential Contact Sensitizers

  • Cosmetics and Fragrances
  • Dyes
  • Preservatives (formaldehyde)
  • Metals (Ni, Co, Be, Cr)
  • Pesticides

(Poison ivy-type reaction

  • delayed type IV)
slide-3
SLIDE 3

Hypersensitivity

Definition excessive humoral or cellular response to an antigen which can lead to tissue damage.

Hypersensitivity reactions are the result of normally beneficial immune responses acting inappropriately.

Two Stages

(Distinguishes from irritation)

Induction Sensitization (1st exposure) Elicitation Challenge (subsequent exposure)

slide-4
SLIDE 4

STRATUM CORNEUM Chemical EPIDERMIS LYMPH NODE

MIGRATION MATURATION

TNF-α RANTES MCP-1 IL-18 IL-1β GM-CSF

IL-1 IL-6 IL-8 IL-10 IL-12 α MIP-2 IP-10 TNF- IFN-γ

MHC class II

Th0

IL-4, IL-5, IL-6, IL-10

Atopic dermatitis

(Type I hypersensitivity) IL-12, INF-γ, TNF-β

Allergic contact dermatitis

(Type IV hypersensitivity)

CD4+

KC

LC

IL-7 IL-15 IL-18 GM-CSF TGF-α TGF-β Key passages

  • 1. Absorption and local

trauma – proinflammatory cytokine production (danger signals)

  • 2. Protein binding
  • 3. Antigen processing
  • 4. Langerhans cells/dermal

DCs maturation and migration

  • 5. Antigen presentation to

Th cells and the generation

  • f memory T cells

(immunogenicity)

HAPTENS bear both the pro-inflammatory properties (adjuvant) and the antigenic properties through binding to self proteins. STRONG haptens are the one with the most adjuvant properties and are therefore able to sensitize the majority

  • f individuals.

WEAK haptens have only limited adjuvant effects and can sensitize a minority of people.

Hapten Carrier Langerhans’ / Dendritic cell dermis Lymphatic Vessel Local Lymph Node keratinocytes :

  • ther cytokines

T M T M T M Blood Vessel T M

  • vascular endothelial cells

inflammation T M T M I I

  • Upon subsequent

contact, some LDC migrate to local lymph node as before. Other LDC present processed hapten-carrier to memory T cells in skin.

  • Activated memory T

cells secrete cytokines that induce release of inflammatory cytokines from other cell types.

  • Memory T cells and

inflammatory cells are recruited to the epidermis from circulation via chemoattractant cytokines and expression

  • f adhesion molecules.

IL-1, IL-6 IFNγ IL-1, Il-6 IL-8, TNFα

Allergic Contact Dermatitis Allergic Contact Dermatitis: : Elicitation Elicitation

slide-5
SLIDE 5

PRESENTATION LAYOUT

  • Introduction to chemical allergy
  • In vivo models
  • In vitro models

Toxicological Approaches to Skin Sensitisation

Well established methods for contact

hypersensitivity.

Current models and assays as

inadequate predictors for system hypersensitivity reaction.

slide-6
SLIDE 6
  • Guinea Pig Tests (OECD 406):

– Maximization Test – Occlusive Patch Test – Respiratory Challenge – Systemic Anaphylaxix

  • Mouse Tests:

– Local lymph node assay (OECD 429) – Mouse Ear Swelling Test

METHODS IN IMMUNOTOXICOLOGY Hypersensitivity Testing

ID injection w/ and without FCA plus topical application: Days 5-8 Day 20-22 topical challenge Read: 48,72 h after challenge

>30% positive

Guinea Pig Guinea Pig Maximization Maximization Test Test

Topical application - closed patch: Days 0, 6-8, and 13-15 Day 27-28 topical challenge

  • f the untreated flank for 6 h

Read: 21, 24, 48 h after removing patch

> 15% positive

Buehler Buehler Assay Assay

Induction Challenge Endpoint erythema

Criteria

20 animals/ group

GUINEA PIG MODELS GUINEA PIG MODELS

slide-7
SLIDE 7

Test/vehicle

LOCAL LYMPH NODE ASSAY

Day 0,1,2 Day 5 2 days of rest, 3H TdR 5 hours T T T T T T T T

IMMUNE ACTIVATION Selective clonal expansion of allergen-responsive T lymphocytes

T

The mouse local lymph node assay (LLNA)

Count DPMs

DNCB in A:OO

B B B B B B

0% 0.01% 0.025% 0.05% 0.1% 0.25% 2 4 6 8 10 12 14 16 18 3-fold dpm ± SE x10 -3

B B B B B B

0% 0.0025% 0.005% 0.01% 0.025% 0.05% 2 4 6 8 10 12 14 16 18

OXAZ in A:OO

dpm ± SE x10 -3 3-fold

HCA in A:OO

B B B B B B

0% 2.5% 5% 10% 25% 50% 2 4 6 8 10 12 14 16 18 dpm ± SE x10 -3 3-fold

LLNA Dose Response Data

slide-8
SLIDE 8
  • Update OECD 429 – Skin sensitization: reduced LLNA

It also includes the Performance Standards that can be used to evaluate the validation status of new and /or modified test methods that are functionall and mechanistically similar to the LLNA.

  • OECD 442A - Skin Sensitization: LLNA DA
  • OECD 442B - Skin Sensitization: LLNA BrdU-ELISA

All adopted 22nd July 2010

NEW OECD GUIDELINES

slide-9
SLIDE 9

PRESENTATION LAYOUT

  • Introduction to chemical allergy
  • In vivo models
  • In vitro models
slide-10
SLIDE 10

Choice of experimental model(s) to study hypersensitivity

STRATUM CORNEUM Chemical EPIDERMIS LYMPH NODE

MIGRATION MATURATION

TNF-α RANTES MCP-1 IL-18 IL-1β GM-CSF

IL-1 IL-6 IL-8 IL-10 IL-12 α MIP-2 IP-10 TNF- IFN-γ

MHC class II

Th0

IL-4, IL-5, IL-6, IL-10

Atopic dermatitis

(Type I hypersensitivity) IL-12, INF-γ, TNF-β

Allergic contact dermatitis

(Type IV hypersensitivity)

CD4+

KC

LC

IL-7 IL-15 IL-18 GM-CSF TGF-α TGF-β

Key events

  • 1. Absorption (metabolism)

and local trauma – proinflammatory cytokine production (danger signals)

  • 2. Protein binding
  • 3. Antigen processing
  • 4. Langerhans cells/dermal

DCs maturation and migration

  • 5. Antigen presentation to

Th cells and the generation

  • f memory T cells

(immunogenicity)

slide-11
SLIDE 11

KERATINOCYTES

  • In principle, a test system comprised of KC

alone may not be useful in establishing allergenic potency as these cells lack antigen presenting capacity. However, in addition to chemical processing, LC activation requires the binding of cytokines produced by KC as a result of initial chemical exposure.

  • Chemical must cause sufficient local trauma

to induce/augment cutaneous cytokine production.

  • The irritant capacity of allergens might

present an additional risk factor so that irritant allergens may be stronger allergens than non-irritant ones (Grabbe et al., 1996). In this case, the potency of chemicals to induce cutaneous sensitization may be assessed as a function of KC cytokine expression.

Chemical LYMPH NODE

MIGRATION MATURATION

TNF-α

RANTES

MCP-1 IL-1β GM-CSF

MHC class II

Th0

CD4 +

slide-12
SLIDE 12

Similar results were also obtained using primary human KC and other keratinocyte cell lines, confirming the relevance of the proposed model and the possibility to use different source of KC Exposure of NCTC 2544 cells to contact allergens results in a dose-related induction of intracellular IL-18, whereas exposure to respiratory allergens and irritants fails to induce IL-18 production

33

slide-13
SLIDE 13

IL-18 SECRETION AS A MARKER FOR IDENTIFICATION OF CONTACT SENSITIZERS IN THE EPIDERM IN VITRO HUMAN SKIN MODEL Deng, W., Oldach, J., Armento, A., Ayehunie, S., Kandarova, H., Letasiova, S., Klausner, M., and Hayden, P. MatTek Corporation, Ashland, MA, USA. Presented at SOT 2011, Abstract #2571

Chemical Tested: 2,4-Dinitrochlorobenzene (DNCB), 2-Mercaptobenzothiazole (2- MBT), 4-Nitrobenzylbromide (4-NBB), Cinnamaldehyde, Cinnamyl Alcohol, Eugenol, Glycerol, Glyoxal, Isoeugenol, Lactic Acid, Phenol, p-Phenylenediamine (ppd), Resorcinol, Salicylic Acid, Tetramethylthiurame disulfide (TMTD)

  • Tier 1 Distinguishes sensitizers from non-sensitizers using NCTC 2544

keratinocyte cell line and IL-18 production (ELISA) as readout.

  • Tier 2 Determines sensitizer potency. Sensitizers selected in tier 1 were

used in tier 2. Epidermal equivalents (EE) were topically exposed for 24 hours to sensitizers selected from tier 1 in a dose response manner and EC50 values were calculated based on the decrease in EE metabolic activity (MTT assay EC50: chemical concentration which results in 50% reduction in cell metabolic activity).

chemical

MTT assay / EC50 calculation

2 4 6 8 25 50 75 100 125

EC50 = 6.778mM DNCB (mM) viable cells (%)

NCTC 2544 chemical IL-18 ELISA

Two tiered cell based assay to distinguish sensitizers from non-sensitizers and to classify sensitizers according to their potency

slide-14
SLIDE 14

Gene Set Enrichment Analysis showed upregulation

  • f “ Keap1

dependent” and “oxidative stress” gene lists. KC expression profiling can identify contact sensitizers. Moreover, data suggest that contact sensitizers induce the oxidative stress pathway in KC.

LANGERHANS CELLS

LC form a sentinel network able to detect, capture, and process antigens such as invading bacteria, viruses, products of tissue damage and haptens. Upon antigen capture, the LC undergo a maturation process leading to the upregulation of co-stimulatory molecules (CD54, CD86, CD80, CD40), MHC class II molecules and the CD83 protein. Thereafter, LC migrate to the T-cell areas of lymphoid organs where they lose antigen-processing activity and become potent immunostimulatory cells.

Chemical LYMPH NODE

MIGRATION MATURATION

TNF-α

RANTES

MCP-1 IL-1β GM-CSF

MHC class II

Th0

CD4 +

slide-15
SLIDE 15

Langerhans cells: restrictions

  • Difficult to isolate from human skin.
  • Low viability.
  • Shortage of available human skin

ALTERNATIVE USE OF LC:

  • Human peripheral blood mononuclear cells
  • CD34+ hematopoietic progenitor cells from cord blood

ALTERNATIVE USE OF DC

  • Use of cell lines such as THP-1, KG-1, MUTZ-3 (human

monocytic leukemia cell lines).

slide-16
SLIDE 16
slide-17
SLIDE 17

KEY EVENT IN VITRO OPPORTUNITIES

  • 1. Skin penetration Human skin biopsis, pig skin;

Reconstituted human epidermis

  • 2. Binding to

macro-molecules (i.e., proteins) QSAR/Expert systems; Peptide binding assay

  • 3. Local trauma and

generation of danger signals KeratinosensTM; KC activation; NCTC2544 IL-18 assay; KC gene expression profile

  • 4. Langerhans cells

maturation and migration DC-like up-regulation of class II antigens and costimulatory molecules, i.e. CD54, CD86; Cytokine release, i.e. IL-8; LC-like MUTZ-3 cells migration assay; DC-like gene expression profile

  • 5. Antigen

presentation to TH cells and memory T-cell generation In vitro T-cell activation

Key events in chemical-induced skin sensitization and in vitro opportunities

Methods under validation at ECVAM

  • THP-1: human Cell Line Activation Test (h-CLAT), chemical

allergens are predicted by the up-regulation of CD86 and CD54 expression when cells are exposed to subtoxic concentrations of chemicals.

  • U937: CD86 upregulation
  • Peptide binding assay: the ability of known chemical

allergens to bind with nucleophilic amino acids has been shown to correlate to the skin sensitization potential of a chemical.

slide-18
SLIDE 18

Methods under validation at JaCVAM

  • THP-1: IL-8 Luc assay

Takahashi T, Kimura Y, Saito R, Nakajima Y, Ohmiya Y, Yamasaki K, Aiba S. An in vitro test to screen skin sensitizers using a stable THP-1-derived IL-8 reporter cell line, THP-G8. Toxicol Sci. 124(2):359-69, 2011 Sep 13.

In vivo toxicity

In vitro model TEST OPTIMIZATION Pre-validation Validation

REGULATORY ACCEPTANCE

VALIDATED TEST

Development of alternative in vitro test

(uninteded stimulation, i.e. contact hypersensitivity)

slide-19
SLIDE 19
  • In vitro methods to assess unintended

contact hypersensitivity are available, although none have been formally validated.

  • These methods can be used in-house for

pre-screening, prioritization, and hazard identification of direct immunotoxicants.

FINAL CONCLUSIONS FINAL CONCLUSIONS